Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Stem Cells and Development|May 31, 2012
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cellsSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Oncotarget|May 27, 2015
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cellsSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Oncotarget|July 21, 2016
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cellsSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Cancer Science|April 24, 2008
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studiesDaigo Akahane, Tetsuzo Tauchi, Seiichi Okabe, et al.
Molecular Cancer Therapeutics|March 27, 2003
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cellsAkihiro Nakajima, Tetsuzo Tauchi, Masahiko Sumi, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 31, 2006
[Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera]Masahiko Sumi, Tetsuzo Tauchi, Tomoiku Takaku, et al.
Cancer Cell International|April 6, 2013
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cellsSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cellsTetsuzo Tauchi, Masahiko Sumi, Akihiro Nakajima, et al.
Leukemia Research Reports|May 3, 2017
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemiaSeiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, et al.
Plos One|July 25, 2024
Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathwayTetsuzo Tauchi, Shota Moriya, Seiichi Okabe, et al.
Pageof 8